Angiotensin-Converting Enzyme 2 (ACE2), Transmembrane Peptidase Serine 2 (TMPRSS2), and Furin Expression Increases in the Lungs of Patients with Idiopathic Pulmonary Fibrosis (IPF) and Lymphangioleiomyomatosis (LAM): Implications for SARS-CoV-2 (COVID-19) Infections.
ACE2
COVID-19
Furin
IPF
LAM
TMPRSS2
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
31 Jan 2022
31 Jan 2022
Historique:
received:
20
01
2022
accepted:
24
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
We previously reported higher ACE2 levels in smokers and patients with COPD. The current study investigates if patients with interstitial lung diseases (ILDs) such as IPF and LAM have elevated ACE2, TMPRSS2, and Furin levels, increasing their risk for SARS-CoV-2 infection and development of COVID-19. Surgically resected lung tissue from IPF, LAM patients, and healthy controls (HC) was immunostained for ACE2, TMPRSS2, and Furin. Percentage ACE2, TMPRSS2, and Furin expression was measured in small airway epithelium (SAE) and alveolar areas using computer-assisted Image-Pro Plus 7.0 software. IPF and LAM tissue was also immunostained for myofibroblast marker α-smooth muscle actin (α-SMA) and growth factor transforming growth factor beta1 (TGF-β1). Compared to HC, ACE2, TMPRSS2 and Furin expression were significantly upregulated in the SAE of IPF (
Identifiants
pubmed: 35160229
pii: jcm11030777
doi: 10.3390/jcm11030777
pmc: PMC8837032
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Med Hypotheses. 2020 Oct;143:109893
pubmed: 32512290
Eur Respir J. 2020 Jul 2;56(1):
pubmed: 32108050
Respir Med Case Rep. 2021;34:101505
pubmed: 34493971
Am J Respir Crit Care Med. 2012 Dec 15;186(12):1210-2
pubmed: 23250499
J Clin Med. 2020 Mar 20;9(3):
pubmed: 32244852
Lancet Respir Med. 2021 Sep;9(9):e93-e94
pubmed: 34216547
Am J Physiol Lung Cell Mol Physiol. 2020 Oct 1;319(4):L585-L595
pubmed: 32726146
Hawaii J Health Soc Welf. 2020 Jul 1;79(7):224-229
pubmed: 32666056
Expert Rev Respir Med. 2021 Feb;15(2):197-212
pubmed: 32924671
Eur Respir J. 2021 Dec 2;58(6):
pubmed: 34857587
Eur Respir J. 2020 May 14;55(5):
pubmed: 32269089
Arch Pathol Lab Med. 2000 Nov;124(11):1642-8
pubmed: 11079017
Am J Physiol Lung Cell Mol Physiol. 2021 Jan 1;320(1):L158-L163
pubmed: 33174446
Am J Physiol Lung Cell Mol Physiol. 2020 Nov 1;319(5):L843-L847
pubmed: 32996784
Biomed Pharmacother. 2020 Nov;131:110678
pubmed: 32861070
Cureus. 2020 Jun 3;12(6):e8432
pubmed: 32642347
Nicotine Tob Res. 2020 Aug 24;22(9):1653-1656
pubmed: 32399563
Clin Chest Med. 2016 Sep;37(3):389-403
pubmed: 27514586
Am J Manag Care. 2019 Jul;25(11 Suppl):S195-S203
pubmed: 31419091
Risk Manag Healthc Policy. 2021 Feb 03;14:379-389
pubmed: 33568956
Respirology. 2021 May;26(5):442-451
pubmed: 33455043
Chest. 2017 Oct;152(4):899-900
pubmed: 28991543
N Engl J Med. 2020 Jun 11;382(24):e92
pubmed: 32427429
Respir Res. 2018 Feb 22;19(1):32
pubmed: 29471816
Lancet Respir Med. 2020 Aug;8(8):807-815
pubmed: 32422178
J Clin Med. 2021 Mar 03;10(5):
pubmed: 33802256
Eur Respir J. 2020 Jul 16;56(1):
pubmed: 32430427
Eur Respir Rev. 2015 Dec;24(138):552-64
pubmed: 26621970
Eur Respir J. 2020 Oct 15;56(4):
pubmed: 32859681
Arch Bronconeumol. 2011 Feb;47(2):85-93
pubmed: 21255897
Eur Respir Rev. 2012 Dec 1;21(126):355-61
pubmed: 23204124
Pharmacol Ther. 2021 Sep;225:107839
pubmed: 33774068
OMICS. 2020 Nov;24(11):634-644
pubmed: 32940573
J Thorac Dis. 2019 May;11(Suppl 9):S1139-S1142
pubmed: 31245065
J Infect. 2019 Nov;79(5):401-406
pubmed: 31465780
Microorganisms. 2020 Jun 18;8(6):
pubmed: 32570850
Eur Respir J. 2021 Feb 11;57(2):
pubmed: 33060154
Eur Respir J. 2021 Dec 2;58(6):
pubmed: 33888524
Eur Respir J. 2021 Aug 26;58(2):
pubmed: 34244320
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Clin Chim Acta. 2020 Nov;510:488-497
pubmed: 32795547
Am J Respir Crit Care Med. 2016 Sep 15;194(6):748-61
pubmed: 27628078